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Background: Nanoparticles fabricated from the biodegradable and biocompatible polymer, 
polylactic-co-glycolic acid (PLGA), are the most intensively investigated polymers for drug 
delivery systems. The objective of this study was to explore fully the development of a PLGA 
nanoparticle drug delivery system for alternative preparation of a commercial formulation. In 
our nanoparticle fabrication, our purpose was to compare various preparation parameters.
Methods: Docetaxel-loaded PLGA nanoparticles were prepared by a single emulsion technique 
and solvent evaporation. The nanoparticles were characterized by various techniques, including 
scanning electron microscopy for surface morphology, dynamic light scattering for size and 
zeta potential, x-ray photoelectron spectroscopy for surface chemistry, and high-performance 
liquid chromatography for in vitro drug release kinetics. To obtain a smaller particle, 0.2% 
polyvinyl alcohol, 0.03% D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), 2% 
Poloxamer 188, a five-minute sonication time, 130 W sonication power, evaporation with 
magnetic   stirring, and centrifugation at 8000 rpm were selected. To increase encapsulation 
efficiency in the nanoparticles, certain factors were varied, ie, 2–5 minutes of sonication time, 
70–130 W sonication power, and 5–25 mg drug loading.
Results: A five-minute sonication time, 130 W sonication power, and a 10 mg drug loading 
amount were selected. Under these conditions, the nanoparticles reached over 90% encapsulation 
efficiency. Release kinetics showed that 20.83%, 40.07%, and 51.5% of the docetaxel was 
released in 28 days from nanoparticles containing Poloxamer 188, TPGS, or polyvinyl alcohol, 
respectively. TPGS and Poloxamer 188 had slower release kinetics than polyvinyl alcohol. It 
was predicted that there was residual drug remaining on the surface from x-ray photoelectron 
spectroscopy.
Conclusion: Our research shows that the choice of surfactant is important for controlled 
release of docetaxel.
Keywords: docetaxel, nanoparticles, poly (lactic-co-glycolic acid), formulation variables, 
sonication, encapsulation efficiency
Introduction
Docetaxel is an anticancer agent of the taxoid family. An analog of paclitaxel, 
  docetaxel was obtained by semisynthesis from 10-deacetyl baccatin III extracted 
from the needles of the European yew tree, Taxus baccata L,1,2 and is more effective 
than paclitaxel as an inhibitor of microtubule polymerization. Docetaxel combined 
with certain other chemotherapeutic drugs shows high anticancer efficacy in breast, 
pancreatic, gastric, and urothelial carcinoma. Docetaxel has very low water solubility, 
and   presently the only available formulation for clinical use consists of a solution International Journal of Nanomedicine  2011:6 submit your manuscript | www.dovepress.com
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(40 mg/mL) in a vehicle containing a high concentration of 
polysorbate 80. This vehicle has been associated with several 
hypersensitivity reactions and exhibits incompatibility with 
common polyvinyl chloride intravenous administration sets.3 
In order to eliminate the polysorbate 80-based vehicle and to 
increase drug solubility, alternative dosage forms have been 
suggested, including liposomes4,5 and cyclodextrins.6
The polymer matrix of nanoparticles must meet several 
requirements, such as biocompatibility, biodegradability, 
mechanical strength, and ease of processing. The best known 
class of biodegradable materials for controlled release is poly 
(lactic acid-co-glycolic acid) (PLGA).7 Many publications 
have described preparation of nanoparticles using PLGA and 
studied formulation variables, including the molecular weight 
of PLGA,8 lyophilizing agents,9 and surfactants.10 Therefore, 
we investigated a sustained injection formulation of docetaxel 
prepared using PLGA by the solvent-evaporation method.11
Formation of an emulsion is the most important step in 
preparation of nanoparticles because the size of the emulsion 
droplets is directly related to the final nanoparticle size. 
This emulsion, which is formed by mixing an organic phase 
  consisting of polymer with an aqueous phase containing 
a surfactant or stabilizer, is broken down into droplets by 
applying external energy, and the nanodroplets lead to 
nanoparticle formation upon evaporation of the organic 
solvent.12
In this study, we focused on the details for preparation 
of docetaxel nanoparticles using PLGA. To obtain a small 
particle size and narrow size distribution, we changed 
some important parameters according to emulsification 
and evaporation. The primary purpose was to identify the 
optimal preparation conditions for nanoparticles of docetaxel 
using PLGA.
Materials and methods
Materials
PLGA (50:50 Resomer RG 502H) with free carboxyl end 
groups was obtained from Boehringer Ingelheim (Ingelheim, 
Germany). Docetaxel was a gift from SamyangGenex 
Corporation (Daejeon, Korea). Polyvinyl alcohol purchased 
from Sigma-Aldrich (Steinheim, Switzerland) was 87%–89% 
hydrolyzed and had a molecular weight of 146,000–186,000. 
Poloxamer 188 was purchased from BASF (Ludwigshafen, 
Germany). D-α-tocopheryl polyethylene glycol 1000 
succinate (TPGS) and sucrose were purchased from Sigma-
Aldrich. All other chemical reagents were commercial 
products of analytical or reagent grade and were used without 
further purification.
Nanoparticle preparation
Nanoparticles containing docetaxel were fabricated by a 
single emulsion technique and solvent evaporation. Briefly, 
docetaxel was dissolved in 2 mL of dichloromethane and then 
100 mg of PLGA was added into the solution. This oil phase 
was emulsified for two minutes with a probe sonicator (VCX 
130, Sonic and Materials, Newtown, CT) at 100 W in an ice 
bath. The resulting oil solution was further emulsified into 
40 mL of aqueous solution containing 0.2% polyvinyl alcohol 
for 10 minutes in an ice bath with sonication. After emulsifica-
tion, the oil-in-water emulsion was magnetically stirred for 
eight hours to evaporate the organic solvent. The nanoparticles 
formed were isolated by centrifugation for 20 minutes at 8000 
rpm. Finally, the nanoparticles were washed with distilled 
water to remove the residual surfactant and then freeze-dried 
in the presence of sucrose. The effects of the various process-
ing parameters on hydrodynamic particle size and percentage 
drug encapsulation efficiency were studied. The processing 
parameters included surfactant concentration and type in the 
aqueous phase, initial drug loading, and sonication pulse time 
and power. Unless otherwise mentioned, all experiments were 
conducted by varying one parameter while keeping all other 
process parameters constant.
Docetaxel assay
The freeze-dried nanoparticles containing docetaxel were 
weighed and dissolved in dichloromethane. After vortexing 
for 15 minutes, dichloromethane was evaporated with nitro-
gen gas. Yield, drug loading, and encapsulation efficiency 
were calculated as follows:
  Yield (%) =   weight of particles 
/weight of feeding polymer and drug  
× 100
Drug loading (%) =   weight of drug in particles 
/weight of particles × 100
Encapsulation efficiency (%) =   weight of drug in particles 
/weight of feeding drugs 
× 100
Particle size, zeta potential, and surface 
tension measurement
Size analysis of the nanoparticles was performed using 
a dynamic light scattering analyzer (ELS-8000, Otasuka 
Electronics, Tokyo, Japan). The nanoparticles containing 
docetaxel was added to the sample dispersion unit and 
sonicated in order to minimize interparticle interactions. International Journal of Nanomedicine  2011:6 submit your manuscript | www.dovepress.com
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The obscuration range was maintained at 2%–50%. The 
instrument was set to measure the sample 30 times, and 
the average volume diameter was obtained. In order to 
measure the zeta potential of the nanoparticles, an aqueous 
dilute suspension of nanoparticles containing docetaxel was 
prepared and sonicated for one minute. The surface tension 
of the nanoparticles containing docetaxel was also checked 
(Sigma 703D, Attension/Biolin Scientific, Espoo, Finland) 
according to the concentration of surfactants.
scanning electron microscopy
Scanning electron microscopy was used to verify uniformity 
of particle shape and size. The lyophilized nanoparticles 
were dropped onto double-sided carbon tape. They were then 
vacuum-coated for 45 seconds with a platinum mixture and 
examined for morphology with a FE-SEM (JEOL JSM7500, 
Thermo Scientific) at 5 kV .
FTIr spectroscopy and x-ray 
photoelectron spectroscopy
Surface structure characteristics of the nanoparticles contain-
ing docetaxel were determined in the solid state using Fourier 
transform infrared spectroscopy (FTIR, Nicolet 380, Thermo 
Scientific). Nanoparticle samples were scanned in the infrared 
range of 400–4000 cm−1. The surface chemistry of the nanopar-
ticles containing docetaxel was checked by x-ray photoelectron 
spectroscopy (Multilab 2000, Thermo Scientific), and the 
  survey spectrum recorded covered a binding energy range from 
0 to 1200 eV using a pass energy of 80 eV . Curve fitting was 
performed using the software supplied by the manufacturer.
In vitro release profiles from  
docetaxel-loaded nanoparticles
Studies of docetaxel release from the nanoparticles containing 
docetaxel were conducted at room temperature in triplicate 
using a semipermeable membrane (molecular weight cutoff 
10,000 Da, MEMBRA-CEL, Chicago, IL) to separate the 
donor and receptor media. The receptor medium was filled 
with 100 mL of pH 7.4 phosphate-buffered solution to ensure 
solubility. A mass of nanoparticles, equivalent to 300 µg of 
docetaxel, was dispersed in the donor medium (5 mL), and 
1 mL samples were withdrawn from the receiver medium at 
a defined time point and replaced with an equivalent volume 
of fresh medium.
statistical analysis
The Student’s t-test was used to compare groups. A P value 
,0.05 was considered to be statistically significant.
Results and discussion
Factors affecting diameter of  
docetaxel-loaded PLgA nanoparticles
The effect of variables in the preparation steps on the mean 
diameter of the docetaxel-loaded PLGA nanoparticles was 
investigated. These variables included the organic solvents, 
concentration of polyvinyl alcohol, TPGS, and Poloxamer 
188 in the aqueous phase, sonication time and power, 
evaporation method, and centrifugation speed.
effect of various organic solvents  
and surfactants
The formation of an emulsion is the most important step in 
nanoparticle preparation because the size of the emulsion 
droplets is directly related to the final nanoparticle size. 
This emulsion, which is formed by mixing an organic phase 
consisting of polymer with an aqueous phase containing 
a   surfactant or stabilizer, is broken down into droplets by 
applying external energy, and these nanodroplets lead to 
nanoparticle formation upon evaporation of the organic 
solvent.12
First, we determined the optimal concentration of 
surfactant, ie, polyvinyl alcohol, TPGS, or Poloxamer 188, 
in the aqueous phase. The concentration of these surfactants 
was varied to identify the effect on particle size, keeping the 
other parameters constant as in the standard procedure.13 
Figure 1 shows the nanoparticle size and surface tension 
according to the concentration of each surfactant in the 
aqueous phase. The surfactant concentration in the aqueous 
phase was varied from 0.1% to 4% for polyvinyl alcohol, 
0.015% to 1% for TPGS, or 0.1% to 4% for Poloxamer 188; 
all other processing parameters, including sonication time 
and drug concentration, were kept constant. An increase in 
polyvinyl alcohol concentration caused a significant decrease 
in nanoparticle size at 0.2% in accordance with the surface 
tension. This was consistent with a low interfacial tension 
that was reduced so that particle size was decreased.14 
Particle size then increased with concentrations above 0.2% 
polyvinyl alcohol. Other researchers have reported that 
increasing the polyvinyl alcohol concentration increases 
the viscosity of the external aqueous phase, resulting in a 
decrease in net shear stress and a corresponding increase in 
particle size.15 A particle size of 44.3 ± 0.7 µm was found 
with 4% Poloxamer 188, and a size of 46.5 ± 1.2 µm was 
found with 2% Poloxamer 188. However, when using TPGS 
in the nanoparticle preparation, surface tension and particle 
size did not show any correlation.International Journal of Nanomedicine  2011:6
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Figure 1 Particle size and surface tension of each formulation with various organic 
solvents and surfactants. (A) PVA, (B) TPgs, and (C) Poloxamer 188. 
Abbreviations: PVA, polyvinyl alcohol; TPgs, D-α-tocopheryl polyethylene glycol 
1000 succinate.
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The predetermined concentration of surfactants was 
2%, 0.03%, and 0.2% for polyvinyl alcohol, TPGS, and 
Poloxamer 188, respectively, in previous experiments. 
Subsequently, three kinds of organic solvents, including 
dichloromethane, chloroform, and ethyl acetate were used. 
With dichloromethane, the size of the nanoparticles was 
290.2 nm, 292.8 nm, and 265.5 nm for Poloxamer 188, 
TPGS, and polyvinyl alcohol, respectively, and the zeta 
potential was −19.27 mV , −3.29 mV , and −16.06 mV, 
respectively. With chloroform, the nanoparticles showed a 
size of 340.5 nm, 531.0 nm, and 274.4 nm with Poloxamer 
188, TPGS, and polyvinyl alcohol, respectively, and the 
zeta potential was 18.94 mV , −20.39 mV , and −16.44 mV , 
respectively. With ethyl acetate, the size of the nanoparticles 
was 438.8 nm, 1044.2 nm, and 393.6 nm with Poloxamer 
188, TPGS, and polyvinyl alcohol, respectively, and the zeta 
potential was −20.75 mV , −14.52 mV , and −19.2 mV , respec-
tively (Figure 2). Based on these results, dichloromethane 
as the organic phase and 0.2% polyvinyl alcohol as the 
aqueous phase showed the smallest particle size. It has also 
been reported that the role of a surfactant is to stabilize the 
emulsion droplets by preventing them from coalescing. For 
effective stabilization, the surfactant molecules have to cover 
the interface between the organic solvent and the aqueous 
phase for all the droplets.12
effect of sonication time and power
The smallest nanoparticles were obtained with sonication for 
five minutes at 130 W (Table 1). Thus, the sonication power 
was likely to decrease the nanoparticle size, probably because 
the sonication energy also increased the energy released by 
emulsification and decreased the mean particle diameter.
effect of evaporation method and time
The method used to remove the organic solvent had a 
significant influence on nanoparticle size. We obtained a 
submicron particle size with a Rotavapor and magnetic 
stirring, but it was impossible to obtain a submicron-sized 
nanoparticle in nitrogen gas and reduced pressure. 
Table 2 shows that nitrogen gas had the fastest evaporation 
rate for organic phase removal, but also resulted in a larger 
particle size than with magnetic stirring. It could be suggested 
that the evaporation rate for removing organic solvent is 
not an important parameter. It is countered that increasing 
evaporation rate of organic solvent influences particle size.16 
Figure 3 shows the effect of different magnetic stirring times 
on removal of the organic solvent during preparation of 
the nanoparticles. With two, four, and six hours of stirring, 
nanoparticles were aggregated but showed a spherical shape. 
Therefore, we concluded that a minimum of eight hours of 
evaporation with magnetic stirring is needed to remove the 
organic solvent.
effect of centrifugation speed
Figure 4 shows nanoparticles prepared at different cen-
trifugation speeds. At 8000 and 10,000 rpm, the nano-
particles had a spherical shape and did not aggregate, but 
  aggregated at 13,000 and 15,000 rpm. Comparing 8000 
and 10,000 rpm, large nanoparticles existed with small 
  particles at 10,000 rpm.International Journal of Nanomedicine  2011:6
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Figure 2 Particle size and zeta potential of each formulation with various organic solvents and surfactants. 
Abbreviations: PVA, polyvinyl alcohol; TPgs, D-α-tocopheryl polyethylene glycol 1000 succinate; DcM, dichloromethane.
Table 1 effects of sonication time and power on nanoparticle characteristics
Sonication time (minutes)  
and power (W)
Particle size,  
mean ± SD (nm)
Zeta potential,  
mean ± SD (mV)
Encapsulation efficiency, 
mean ± SD (%)
2, 70 514.5 ± 53.1  − 4.64 ± 0.88 87.56 ± 3.51
2, 100 422.0 ± 22.1  − 9.37 ± 0.76 57.75 ± 5.67
2, 130 380.6 ± 42.4  − 8.63 ± 2.64 75.41 ± 3.25
5, 70 478.6 ± 60.2  − 4.39 ± 1.52 74.04 ± 3.87
5, 100 290.1 ± 35.6 −12.45 ± 2.37 77.41 ± 8.67
5, 130 234.5 ± 20.1 −11.40 ± 1.65 89.83 ± 2.75
10, 70 498.7 ± 45.4  − 2.54 ± 1.89 60.69 ± 8.48
10, 100 423.9 ± 41.6  − 7.52 ± 0.78 79.90 ± 6.44
10, 130 427.5 ± 16.4  − 7.56 ± 2.21 93.31 ± 1.56
Abbreviation: sD, standard deviation.
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Factors affecting encapsulation efficiency 
of docetaxel-loaded nanoparticles
The effect of variables in the preparation steps on the encap-
sulation efficiency of docetaxel-loaded PLGA nanoparticles 
was investigated. These included the mixing order of the 
organic phase, drug amount, sonication time and power, types 
of organic solvents, and concentration of polyvinyl alcohol, 
TPGS, or Poloxamer 188 in the aqueous phase.
effect of mixing order for organic phase
To optimize the amount of docetaxel-loaded PLGA nanopar-
ticles, various experimental conditions for the preparation of 
these particles were evaluated. The influence of preparation 
of the organic phase on the particles was evaluated, and the 
effect on the encapsulation efficiency of docetaxel is given 
in Table 3. Only 3.64%–10.03% of the initial drug load 
was encapsulated in the nanoparticles, except when the 
organic phase was prepared using F4, which gave a 78.78% 
encapsulation efficiency. Therefore, F4 was selected for 
preparation of the organic phase. This may have resulted from 
a different interaction between docetaxel and the polymer 
occurring when they are both solubilized, thus leading to 
different encapsulation in the nanoparticles.17 F4 and the 
other preparations also have different polymer concentrations 
and mixing methods, and an interaction between drug and 
polymer may occur.
effect of drug amount
Table 4 shows the effect of initial drug amount on encapsula-
tion efficiency. As the initial amount of drug increased, the 
encapsulated drug first increased and then decreased with an 
initial drug amount of 25 mg. The maximum encapsulated 
drug amount was 10 mg of docetaxel. In our experiments, 
as the initial drug amount increased during formulation, the 
drug concentration in the organic phase also increased. This 
means that more drug molecules could interact with the PLGA 
molecules, resulting in an increase in the amount of docetaxel 
encapsulated. However, the increase in encapsulation amounts 
was not proportional to the increase in initial drug amounts dur-
ing formulation, so the encapsulation efficiency decreased.International Journal of Nanomedicine  2011:6
Figure 3 scanning electron microscopic images of polylactic acid-co-glycolic acid 
nanoparticles  with  various  magnetic  stirring  times  to  remove  organic  solvent. 
(A), two hours, (B), four hours, (C), six hours, and (D) eight hours.
Table 3 Encapsulation efficiency according to mixing order of 
docetaxel and PLgA
Formulation Mixing order of docetaxel  
and PLGA
Encapsulation 
efficiency  
Mean ± SD (%)
F1 Docetaxel and PLgA were  
solubilized in DcM (vortexed)
10.03 ± 1.68
F2 Docetaxel and PLgA were  
solubilized in DcM (sonicated)
  4.13 ± 2.31
F3 PLgA was added into docetaxel- 
DcM solution and add DcM  
(vortexed)
  3.64 ± 1.78
F4 PLgA was added into docetaxel- 
DcM solution and add DcM  
(sonicated)
78.78 ± 6.13
F5 Docetaxel-DcM solution mixed  
with PLgA-DcM solution  
(sonicated)
  8.62 ± 3.08
Abbreviations: sD, standard deviation; DcM, dichloromethane; PLgA, polylactic-
co-glycolic acid.
Table 2 effect of evaporation equipment on size of nanoparticles
Solvent evaporation method Particle size 
Mean ± SD (nm)
rotavapor (1 hour)   776.9 ± 39.5
stirring overnight (8 hours)   563.6 ± 24.8
Nitrogen gas (30 minutes) 1284.3 ± 115.7
reduced pressure (1 hour) 2569.7 ± 909.7
Abbreviation: sD, standard deviation.
Figure 4 scanning electron microscopic images of polylactic acid-co-glycolic acid 
nanoparticles with different centrifugation speeds. (A) 8000, (B) 10,000, (C) 13,000, 
and (D) 15,000.
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effect of extent of sonication
Table 1 shows the effects of different sonication   parameters 
on encapsulation efficiency. For five and 10 minutes, 
encapsulation efficiency increased with increasing sonication 
power. However, for two minutes, the higher energy released 
in the process led to low encapsulation efficiency. These 
results suggest that increased sonication power with five or 
10 minutes leads to more encapsulated nanoparticles. With 
two minutes of sonication, a sonication power above 70 W 
was too high to make a stable nanosuspension.
effect of various organic solvents  
and surfactants
Figure 5 shows the encapsulation efficiencies of docetaxel. The 
encapsulation efficiency of docetaxel decreased significantly 
with chloroform. The same solvent prepared with TPGS led 
to the lowest encapsulation efficiency, and polyvinyl alcohol 
led to the highest encapsulation efficiency.
X-ray photoelectron spectroscopy  
and FTIr analysis
X-ray photoelectron spectroscopy is a quantitative technique 
that gives the elemental and averaged chemical composition 
by measuring the binding energy of electrons associated with 
atoms over a 5–10 nm depth inside the polymeric matrix.18 
X-ray photoelectron spectroscopy C1s (atomic orbital 1s 
of carbon) envelopes on the surface of docetaxel-loaded International Journal of Nanomedicine  2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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nanoparticles and its components were examined and the 
results are displayed in Table 5. Firstly, there was a nitrogen 
signal detected in the physical mixture and nanoparticles, 
which could mean that docetaxel was on the surface. The 
nitrogen signal found only in docetaxel could be evidence of 
docetaxel existing on the surface of nanoparticles.18
The infrared spectra of the docetaxel nanoparticles 
are shown in Figure 6. The major peak of docetaxel was 
around 1725 cm−1 (ester stretching) and PLGA showed the 
characteristic vibration of carboxylic acid at 1750 cm−1. 
FTIR spectra for the physical mixture showed a major peak 
of docetaxel and PLGA. However, in the FTIR spectra for 
docetaxel nanoparticles, the major peak of docetaxel was 
significantly lowered. This indicated a chemical interaction 
between docetaxel and PLGA,19 by which the carboxylic acid 
in PLGA interacted with the ester group in docetaxel, and the 
ester absorption frequency was correspondingly lowered.20
In vitro release with various surfactants 
and organic solvents
Figure 7A shows the in vitro release kinetics for the three 
types of docetaxel-loaded nanoparticles. For all surfactants, 
an initial burst was observed. After that, the release of 
  docetaxel occurred at a constant rate. Obviously, docetaxel 
was released more slowly from the nanoparticles formulated 
with TPGS and Poloxamer 188 than those formulated with 
polyvinyl alcohol. Diffusion of the drug, erosion, swelling of 
the polymer matrix, and degradation of the polymer are the 
main mechanisms for drug release. Since the degradation of 
PLGA is slow,18 release of docetaxel from the nanoparticles 
would depend mainly on drug diffusion and matrix erosion. 
In such cases, the size, hardness, and porosity of the nano-
particles should significantly affect the release properties. 
Scanning electron microscopy indicated that all types of 
nanoparticles had a smooth surface, which supported the 
slow release of drug.21 Moreover, size is also an important 
factor that determines the release rate, and the nanoparticles 
prepared by TPGS, polyvinyl alcohol, and Poloxamer 188 
were similar in size.21 TPGS and Poloxamer 188 are bulky 
and have a large surface area. Thus, the nanoparticles emulsi-
fied by TPGS exhibit slower in vitro release than those with 
polyvinyl alcohol, which has different surface properties.21 
Figure 7B shows the in vitro release kinetics for the three 
types of docetaxel-loaded nanoparticles. For all organic 
Table 4 effect of drug amount on nanoparticle characteristics
Drug amount (mg) Particle size,  
mean ± SD (nm)
Zeta potential,  
mean ± SD (mV)
Encapsulation efficiency,   
mean ± SD (%)
0 232.8 ± 11.6 – –
5 286.3 ± 9.4 −17.7 ± 1.3 60.5 ± 1.9
10 269.4 ± 2.9  − 8.4 ± 1.6 97.4 ± 4.8
15 282.1 ± 10.2  − 4.9 ± 1.4 61.1 ± 13.7
20 282.1 ± 23.4   5.9 ± 2.3 49.7 ± 8.6
25 285.3 ± 11.7   13.8 ± 3.1 38.7 ± 2.9
Abbreviation: sD, standard deviation.
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Table 5 X-ray photoelectron spectroscopy for surface chemistry
Sample XPS C1s envelope ratio (%) XPS elemental ratio (%)
C–C C–O C=O O–C=O C N O
rg502 1.6 13.8 23.5 18.9 57.8 42.2
PVA 31.4 30.8 4.1 66.2 33.8
TPgs 29.4 39.2 1.8 70.3 29.7
Docetaxel 49.0 16.2 3.6 4.4 73.2 2.0 25.1
sucrose 4.8 40.4 6.4 51.6 48.4
Physical mixture 0.5 43.1
Blank nanoparticles 28.7 18.3 5.6 11.4 64.1 35.9
Docetaxel PLgA nanoparticles 29.3 17.5 7.3 8.1 62.2 0.4 37.4
Abbreviations: sD, standard deviation; DcM, dichloromethane; PLgA, polylactic-co-glycolic acid; PVA, polyvinyl alcohol; TPgs, D-α-tocopheryl polyethylene glycol 1000 
succinate; XPs, x-ray photoelectron spectroscopy.
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Figure 6 Fourier transform infrared spectroscopy for surface chemistry. 
Abbreviations: PVA, polyvinyl alcohol; DTX, docetaxel; PLgA, polylactic acid-co-glycolic acid.
  solvents, an initial burst was observed. After that, the release 
of docetaxel occurred at a constant rate. The mean release rate 
of ethyl acetate was slower than that of dichloromethane and 
chloroform. However, the three organic solvents did not 
affect the slow-release kinetics.
Conclusion
The influence of various processing parameters on particle 
size and drug encapsulation efficiencies was systematically 
investigated. It was concluded that formulation variables can 
be developed in order to enhance the encapsulation of a hydro-
phobic drug into PLGA nanoparticles using an o/w emulsifica-
tion method. With the optimal parameters, small particles with 
a spherical shape could be obtained. The size of the nanopar-
ticles could be adjusted by modifying various process param-
eters explicitly, such as surfactant type and   concentration, 
sonication parameters, evaporation parameters, and centrifuga-
tion parameters. To obtain a smaller particle, 0.2% polyvinyl 
alcohol, 0.03% TPGS, or 2% Poloxamer 188, five minutes of 
sonication time, 130 W sonication power, evaporation with 
magnetic stirring, and centrifugation at 8000 rpm, were 
selected. The encapsulation efficiency of drug was dependent 
on different formulation factors, such as mixing order, sonica-
tion time and power, drug loading amount, type of surfactant, 
and organic solvent. To increase the encapsulation efficiency 
in the nanoparticles, factors were varied from 2–5 minutes of 
sonication time, 70–130 W sonication power, and a 5–25 mg 
drug loading amount. As a result, five minutes of sonication 
time, 130 W sonication power, and a drug loading amount of 
10 mg were selected. Docetaxel showed different release from 
the nanoparticles over a 28-day period with different types of 
organic solvents and   surfactants. In the release kinetics, International Journal of Nanomedicine  2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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PLgA nanoparticles of docetaxel
20.83%, 40.07%, and 51.5% of docetaxel were released in 
28 days from nanoparticle with Poloxamer 188, TPGS, and 
polyvinyl alcohol, respectively.   Comparing the release kinetics 
with various surfactants, TPGS and Poloxamer 188 had slower 
release kinetics than polyvinyl alcohol. X-ray photoelectron 
spectroscopy demonstrated that residual drug remained on the 
surface. This study confirmed that variable factors affect mean 
nanoparticle diameter, encapsulation efficiency, and release 
kinetics.
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